United Kingdom · Question · Written question
HL HL17221
Armed Forces: Mefloquine
Introduced
16 July 2019
Last action
22 July 2019 · Answer
Status
Answered
Sponsors
—
Subjects
Defence
Source updated
22 July 2019
Summary
To ask Her Majesty's Government, further to the Written Answer by Baroness Blackwood of North Oxford on 10 July (HL16834), what steps the Ministry of Defence has taken to address the concerns of the European Medicines Agency Pharmacovigilance Assessment C
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
16 July 2019
Written question
To ask Her Majesty's Government, further to the Written Answer by Baroness Blackwood of North Oxford on 10 July (HL16834), what steps the Ministry of Defence has taken to address the concerns of the European Medicines Agency Pharmacovigilance Assessment C
Source: Lords
22 July 2019
Answer
Anti-malarial drugs are prescribed to Service personnel with the UK product information leaflet. For mefloquine, this reflects the recommendations of the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency.All anti-malarial drugs ...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Ministry of Defence · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2019-07-16/HL17221
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1139574
- uk · wq-1139574 · source updated 22 July 2019